Promethazine Dosing for Acute Vertigo
For acute peripheral vertigo in adults, administer promethazine 25 mg intramuscularly or intravenously (infused slowly at ≤25 mg/min), which can be repeated every 4-6 hours as needed, with a maximum total daily dose of 50-100 mg. 1
Route of Administration
Intramuscular (IM) administration is preferred over intravenous (IV) due to serious safety concerns. The FDA updated labeling in 2023 emphasizing preference for IM route to minimize risk of limb-threatening complications from inadvertent intra-arterial injection or perivascular extravasation, which can cause tissue necrosis and gangrene 2, 3.
If IV administration is necessary:
- Dilute the medication appropriately
- Infuse slowly at maximum rate of 25 mg/min to minimize hypotension risk 2
- Ensure proper IV line placement before administration
Specific Dosing Regimen
Initial Dose
- 25 mg IM or IV (slow infusion) 1, 4
- Clinical effects evident within 5 minutes of IV administration 2
- Duration of action: 4-6 hours 2
- Plasma half-life: 9-16 hours 2
Repeat Dosing
- May repeat 12.5-25 mg every 4-6 hours as necessary 1
- Maximum daily dose: 50-100 mg when used as adjuvant therapy 5
Duration of Treatment
The FDA label indicates dosing for acute episodes without specifying maximum treatment duration 1. Research studies typically used single doses or short courses (≤5 days) 6, 4, 7.
Evidence for Efficacy in Vertigo
While the FDA label does not specifically list vertigo as an approved indication 1, high-quality research demonstrates promethazine's superiority over alternatives for acute peripheral vertigo:
- Promethazine 25 mg IV reduced vertigo by 46.5 mm on VAS versus lorazepam 2 mg IV (25.7 mm reduction), p<0.001 4
- Promethazine IM showed greater vertigo reduction than oral betahistine at 2-3 hours post-administration 6
- Promethazine was more effective than ondansetron for vertigo relief, though ondansetron was superior for nausea control 7
Critical Safety Considerations
Serious Adverse Effects
- Tissue necrosis and gangrene with extravasation or intra-arterial injection 2, 3
- Respiratory depression (particularly when combined with opioids or benzodiazepines) 2
- Extrapyramidal effects ranging from restlessness to oculogyric crises 2
- Neuroleptic malignant syndrome (rare) 2
- Hypotension (minimize by slow IV infusion) 2
Common Side Effects
- Drowsiness/sedation (most common, reported in 10.8% of patients) 4
- Burning or pain at injection site 2
Contraindications
- Children under 2 years of age (black box warning) 1
- Use caution in elderly or frail patients
Clinical Context: When NOT to Use Vestibular Suppressants
Important caveat: The 2008 BPPV guideline specifically recommends against routine use of vestibular suppressant medications (including promethazine) for benign paroxysmal positional vertigo, as they are ineffective as primary treatment and no substitute for repositioning maneuvers 8.
Promethazine should be reserved for:
- Acute peripheral vertigo (vestibular neuritis, labyrinthitis, Meniere's disease) 6, 4, 7
- Short-term management of severe vegetative symptoms (nausea/vomiting) in BPPV patients who refuse or cannot tolerate repositioning maneuvers 8
Dose Reduction Considerations
While standard dosing is 25 mg, lower doses (6.25-12.5 mg IV) may provide equivalent antiemetic efficacy with potentially fewer sedative effects 9. However, research specifically for vertigo used the standard 25 mg dose 6, 4, 7.
When promethazine is used with narcotics or benzodiazepines, dose reduction of standard sedation agents may be required 2.